Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Finished Goods (2017 - 2023)

Perspective Therapeutics' Finished Goods history spans 11 years, with the latest figure at $20000.0 for Q3 2023.

  • For Q3 2023, Finished Goods fell 25.93% year-over-year to $20000.0; the TTM value through Sep 2023 reached $20000.0, down 25.93%, while the annual FY2022 figure was $21000.0, N/A changed from the prior year.
  • Finished Goods for Q3 2023 was $20000.0 at Perspective Therapeutics, up from $18000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $49000.0 in Q2 2021 and bottomed at $7000.0 in Q4 2019.
  • The 5-year median for Finished Goods is $21000.0 (2022), against an average of $22368.4.
  • The largest annual shift saw Finished Goods tumbled 72.97% in 2019 before it surged 314.29% in 2021.
  • A 5-year view of Finished Goods shows it stood at $7000.0 in 2019, then changed by 0.0% to $7000.0 in 2020, then soared by 314.29% to $29000.0 in 2021, then dropped by 27.59% to $21000.0 in 2022, then decreased by 4.76% to $20000.0 in 2023.
  • Per Business Quant, the three most recent readings for CATX's Finished Goods are $20000.0 (Q3 2023), $18000.0 (Q2 2023), and $15000.0 (Q1 2023).